Wintac’s board has approved the proposal to effect slump sale of the Pharmaceutical Business Undertaking of the company to Par Formulations. The board of directors of the company at their meeting held on April 26, 2018, considered and approved the same.
Besides, the Board approved the business transfer agreement to be entered into with Par Formulations.
Wintac is a professionally managed and fully integrated pharmaceutical company that is committed in developing, manufacturing and marketing of high quality pharmaceutical formulations using innovative technologies and meeting the cGMP standards which are continuously updated to international requirements.
